Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

  • End date
    Apr 30, 2023
  • participants needed
  • sponsor
    Peking University
Updated on 23 January 2021
ct scan
t-cell lymphoma
anaplastic large cell lymphoma
large cell lymphoma


Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for newly diagnosed peripheral T-cell lymphoma (PTCL).


This is a open-label, multi-center, randomized, non-inferiority study to compare efficacy and safety of CDOP with standard CHOP regimen in patients with previously untreated PTCL. Study subjects are patients with histologically proven newly diagnosed PTCL. Patients are randomized 1:1 to receive either cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles or cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.This study is divided into three phases: screening phase, treatment phase and follow-up phase. Patients will receive study drug(s) for up to 6 cycles, or until unacceptable toxicity will develop or progression or voluntary withdrawal.Adverse event of every treatment cycle will be recorded.Therapy efficacy will be evaluated after finishing 2 cycles, 4cycles and finishing 6 cycles therapy. Patients will be followed until disease progression, died or 2 years from the last patient randomized.

Condition Peripheral T-Cell Lymphoma, T-Cell Lymphoma
Treatment cyclophosphamide, prednisone, vincristine, doxorubicin, Pegylated Liposomal Doxorubicin
Clinical Study IdentifierNCT03952572
SponsorPeking University
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have Peripheral T-Cell Lymphoma?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or T-Cell Lymphoma?
Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL not otherwise specifiedPTCL-NOS, angioimmunoblastic T cell lymphomaAITL, anaplastic large cell lymphomaALCLand other peripheral T-cell lymphoma(except NK/T cell lymphoma)
Males and females of 18 years of age to 75 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0- 2
At least 1 single size measurable lesions, CT or PET-CT scan shows more than 15mm
Estimated survival time 6 months
Liver function: transaminases3ULNor transaminases3ULN for liver metastasistotal bilirubin 1.5ULNor total bilirubin 2.5ULN for Gilbert's syndrome
Renal function: serum creatinine 1.5ULN or creatinine clearance 60 ml / min ( standard Cockcroft-Gault formula)
peripheral hemogram: WBC3.010^9/L, ANC1.510^9/L, Hb90g/L, PLT7510^12/L
Cardiac ultrasound LVEF55%
New York Heart Association (NYHA) heart function classification is I grade
sign informed consent

Exclusion Criteria

Patients with primary or secondary central nervous system lymphoma
Serious heart disease, including but not limited to
)Significant ventricular arrhythmia or high degree atrioventricular block
(Mobitz II or third degree atrioventricular block); 2) unstable angina; 3)
clinically significant heart valve disease; 4) Electrocardiogram shows
transmural myocardial infarction; 5) Uncontrollable hypertension; 3
interstitial pneumonia, allergic asthma or severe allergic medical history
Patients with other malignancies in the past or now (except basal cell
carcinoma, squamous-cell carcinoma or carcinoma in situs of cervix that has
been adequately treated), 5.HIV antibody positivity; 6.Acute or chronic active
hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic
active hepatitis C (HCV antibody negatively acceptable; HCV antibody
positivity, HCV RNA negative acceptable) 7.Pregnancy or lactation period
Patients with Organ transplantation 9.Patients with serious uncontroled
acute infection 10.High doses of hormones are contraindicated, such as
uncontrolled hyperglycemia, stomach ulcers or Mental illness, etc
Patients with severe neurological or psychiatric history, including
dementia or epilepsy 12.The researchers considered that patients are not
suitable for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note